ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system will be incorporated into a clinical study to provide an early warning of relapse among patients being treated for non-small cell lung cancer.
The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group and will be deployed to track circulating tumour DNA, fragments of dead cancer cells and circulating tumour cells (CTCs).
A total of 50 operable early-stage patients will have blood drawn prior to surgery, one month after the operation and then every three to six months until relapse.
CTC evaluation is being undertaken by the University of Athens, lead by Professor Evi Lianidou, and the latest collaboration builds on work by the same team using Parsortix in research on head and neck cancer.
"This is another example of ANGLE's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer,” said ANGLE chief executive Andrew Newland.
“The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE."
Shares in ANGLE held steady at 67p in late afternoon trading on Friday.
-- Adds share price --